MARKET

MGNX

MGNX

Macrogenics Inc
NASDAQ
4.860
+0.240
+5.19%
After Hours: 4.890 +0.03 +0.62% 19:58 06/02 EDT
OPEN
4.640
PREV CLOSE
4.620
HIGH
4.870
LOW
4.630
VOLUME
388.06K
TURNOVER
0
52 WEEK HIGH
7.90
52 WEEK LOW
2.130
MARKET CAP
300.54M
P/E (TTM)
-3.2760
1D
5D
1M
3M
1Y
5Y
Macrogenics Inc: Statement of changes in beneficial ownership of securities
Press release · 1d ago
Macrogenics Inc: Current report
Press release · 1d ago
MacroGenics: Non-Dilutive Funding Propels Drug Candidates (Rating Upgrade)
Seeking Alpha · 5d ago
Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS) and MacroGenics (MGNX)
TipRanks · 05/12 01:30
MacroGenics (MGNX) Gets a Buy from SVB Securities
TipRanks · 05/11 16:46
--JMP Securities Adjusts Price Target on MacroGenics to $10 From $8, Maintains Market Outperform Rating
--JMP Securities Adjusts Price Target on MacroGenics to $10 From $8, Maintains Market Outperform Rating
MT Newswires · 05/11 11:17
JMP Securities Maintains Market Outperform on Macrogenics, Raises Price Target to $10
Benzinga · 05/11 10:56
JMP Securities Sticks to Their Buy Rating for MacroGenics (MGNX)
TipRanks · 05/11 04:45
More
About MGNX
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.

Webull offers kinds of MacroGenics Inc stock information, including NASDAQ:MGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MGNX stock methods without spending real money on the virtual paper trading platform.